SCHEMBL975944

SCHEMBL975944

C[C@@H](OC(=O)OC1CC(=O)NC1=O)OC(=O)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.39
SLC6A4 P31645 3/20 0.38
SLC6A3 Q01959 3/20 0.38
LMNA P02545 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
SCN1A P35498 1/20 0.38
SCN2A Q99250 1/20 0.38
SCN3A Q9NY46 1/20 0.38
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
PDCD1 Q15116 1/20 0.37
CD274 Q9NZQ7 1/20 0.37
ALOX15 P16050 1/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
DDB1 Q16531 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2957623 1.00 GAA (0.39) GAASLC6A4SLC6A3LMNACYP1A2
SCHEMBL1068302 0.81 GAA (0.48) GAALMNATSHRALDH1A1DDB1
SCHEMBL6667157 0.81 HCAR2 (0.43) CYP1A2TP53TSHRALOX15ALDH1A1
Ammonia Solution, Strong SCHEMBL9774304 0.80 GAA (0.47) GAALMNATSHRALDH1A1DDB1
SCHEMBL978471 0.79
SCHEMBL612318 0.79
SCHEMBL4556983 0.78 TDP1 (0.45) GAASLC6A3LMNACYP1A2SCN1A
SCHEMBL5091923 0.78 TDP1 (0.45) GAASLC6A3LMNACYP1A2SCN1A
SCHEMBL1883113 0.78 CES2 (0.41) GAASLC6A3LMNATSHRALDH1A1
SCHEMBL4528310 0.76 RAB9A (0.39) SLC6A4SLC6A3ALDH1A1RAB9ADDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868043-B2 Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use XENOPORT, INC. (US) 2011-01-11 US disclosed
WO-2009094577-A2 MESOPHASIC FORMS OF (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUGS AND METHODS OF USE XENOPORT, INC. (US) 2009-07-30 WO disclosed
US-20090192222-A1 MESOPHASIC FORMS OF (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUGS AND METHODS OF USE XENOPORT, INC. (US) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192222-A1 MESOPHASIC FORMS OF (3S)-AMINOMETHYL-5-METHYL-HEXANOIC ACID PRODRUGS AND METHODS OF USE SI, ACMSD, HMBS GAA 724/4885SLC6A4 439/4885SLC6A3 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.